Zacks Investment Research on MSN
NVO Q4 earnings & sales beat estimates, stock down on poor 2026 view
Novo Nordisk A/S NVO reported adjusted fourth-quarter 2025 earnings of $1 per American Depositary Receipt (ADR), which beat ...
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.
Telehealth for FQHCs and RHCs: Federally qualified health centers (FQHCs) and rural health clinics (RHCs) may continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results